Rocket Pharmaceuticals, Inc. (RCKT) Current Ratio
- Current ratio · latest quarter: Value 9.24×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.24× | Current assets / current liabilities. $289.55M ÷ $31.32M ≈ 9.24× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 289.55M USD | Assets, Current |
| Current obligations | 31.32M USD | Liabilities, Current |
| Cash and equivalents | 224.51M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $289.55M | $31.32M | $224.51M | (m) | (m) | (m) | (m) | (m) | 9.24× |
| 2026-03-31 | $149.83M | $24.47M | $49.61M | (m) | (m) | (m) | (m) | (m) | 6.12× |
| 2025-12-31 | $192.73M | $30.21M | $77.56M | (m) | (m) | (m) | (m) | (m) | 6.38× |
| 2025-09-30 | $227.68M | $31.17M | $75.95M | (m) | (m) | (m) | (m) | (m) | 7.30× |
| 2025-06-30 | $277.15M | $43.40M | $32.82M | (m) | (m) | (m) | (m) | (m) | 6.39× |
| 2025-03-31 | $324.49M | $35.31M | $49.81M | (m) | (m) | (m) | (m) | (m) | 9.19× |
| 2024-12-31 | $378.18M | $40.68M | $163.63M | (m) | (m) | (m) | (m) | (m) | 9.30× |
| 2024-09-30 | $241.75M | $39.98M | $65.60M | (m) | (m) | (m) | (m) | (m) | 6.05× |
| 2024-06-30 | $292.73M | $37.59M | $38.61M | (m) | (m) | (m) | (m) | (m) | 7.79× |
| 2024-03-31 | $345.16M | $32.96M | $35.28M | (m) | (m) | (m) | (m) | (m) | 10.47× |
| 2023-12-31 | $378.22M | $48.51M | $55.90M | (m) | (m) | (m) | (m) | (m) | 7.80× |
| 2023-09-30 | $446.87M | $33.48M | $225.66M | (m) | (m) | (m) | (m) | (m) | 13.35× |
| 2023-06-30 | $312.07M | $34.35M | $45.08M | (m) | (m) | (m) | (m) | (m) | 9.09× |
| 2023-03-31 | $338.03M | $31.21M | $64.58M | (m) | (m) | (m) | (m) | (m) | 10.83× |
| 2022-12-31 | $364.06M | $39.17M | $140.52M | (m) | (m) | (m) | (m) | (m) | 9.29× |
| 2022-09-30 | $311.13M | $30.18M | $196.67M | (m) | (m) | (m) | (m) | (m) | 10.31× |
| 2022-06-30 | $325.77M | $24.29M | $187.55M | (m) | (m) | (m) | (m) | (m) | 13.41× |
| 2022-03-31 | $353.85M | $22.57M | $130.55M | (m) | (m) | (m) | (m) | (m) | 15.68× |
| 2021-12-31 | $392.06M | $22.17M | $232.69M | (m) | (m) | (m) | (m) | (m) | 17.69× |
| 2021-09-30 | $425.07M | $24.49M | $245.64M | (m) | (m) | (m) | (m) | (m) | 17.36× |
| 2021-06-30 | $430.43M | $25.44M | $264.61M | (m) | (m) | (m) | (m) | (m) | 16.92× |
| 2021-03-31 | $471.82M | $40.49M | $252.54M | (m) | (m) | (m) | (m) | (m) | 11.65× |
| 2020-12-31 | $487.35M | $32.62M | $297.10M | (m) | (m) | (m) | (m) | (m) | 14.94× |
| 2020-09-30 | $233.21M | $31.95M | $82.23M | (m) | (m) | (m) | (m) | (m) | 7.30× |
| 2020-06-30 | $255.44M | $20.68M | $163.20M | (m) | (m) | (m) | (m) | (m) | 12.35× |
| 2020-03-31 | $279.81M | $21.11M | $190.52M | (m) | (m) | (m) | (m) | (m) | 13.25× |
| 2019-12-31 | $307.75M | $18.31M | $185.38M | (m) | (m) | (m) | (m) | (m) | 16.81× |
| 2019-09-30 | $245.59M | $22.18M | $89.19M | (m) | (m) | (m) | (m) | (m) | 11.07× |
| 2019-06-30 | $263.63M | $15.08M | $64.83M | (m) | (m) | (m) | (m) | (m) | 17.48× |
| 2019-03-31 | $199.62M | $20.57M | $124.46M | (m) | (m) | (m) | (m) | (m) | 9.70× |
| 2018-12-31 | $209.09M | $15.37M | $111.36M | (m) | (m) | (m) | (m) | (m) | 13.60× |
| 2018-09-30 | $128.82M | $10.29M | $38.08M | (m) | (m) | (m) | (m) | (m) | 12.51× |
| 2018-06-30 | $134.61M | $10.15M | $52.55M | (m) | (m) | (m) | $66.00K | (m) | 13.27× |
| 2018-03-31 | $184.83M | $7.34M | $171.14M | (m) | (m) | (m) | $67.00K | (m) | 25.19× |
| 2017-12-31 | $18.95M | $4.52M | $18.14M | (m) | (m) | (m) | (m) | (m) | 4.19× |
| 2017-09-30 | $103.87M | $3.77M | $49.15M | (m) | (m) | (m) | $383.00K | (m) | 27.57× |
| 2017-06-30 | $109.82M | $4.02M | $27.61M | (m) | (m) | (m) | $368.00K | (m) | 27.35× |
| 2017-03-31 | $116.63M | $5.27M | $25.27M | (m) | (m) | (m) | $1.90M | (m) | 22.14× |
| 2016-12-31 | $128.35M | $7.04M | $29.80M | (m) | (m) | (m) | $1.59M | (m) | 18.23× |
| 2016-09-30 | $138.92M | $5.94M | $83.00M | (m) | (m) | (m) | $1.78M | (m) | 23.37× |
| 2016-06-30 | $98.70M | $4.07M | $38.52M | (m) | (m) | (m) | $921.00K | (m) | 24.25× |
| 2016-03-31 | $103.25M | $4.61M | $58.71M | (m) | (m) | (m) | $1.38M | (m) | 22.38× |
| 2015-12-31 | $112.37M | $4.14M | $80.04M | (m) | (m) | (m) | $1.63M | (m) | 27.13× |
| 2015-09-30 | $119.22M | $3.24M | $89.25M | (m) | (m) | (m) | $1.71M | (m) | 36.76× |
| 2015-06-30 | $49.48M | $2.45M | $49.01M | (m) | (m) | (m) | $813.00K | (m) | 20.18× |
| 2015-03-31 | $53.44M | $2.46M | $53.14M | (m) | (m) | (m) | $1.30M | (m) | 21.75× |
| 2014-12-31 | $3.67M | $7.22M | $3.62M | (m) | (m) | (m) | $1.15M | (m) | 0.51× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |